Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk

Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits

Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk